Pharvaris
PHVS

Pharvaris (PHVS) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
GuggenheimMaintainedBuy$44.00 from $40.00Sep 10, 2026
WedbushMaintainedOutperform$50.00 from $42.00Sep 9, 2026
RBC CapitalMaintainedOutperform$62.00 from $52.00Sep 9, 2026
Wells FargoMaintainedOverweight$65.00 from $55.00Sep 9, 2026
CitizensMaintainedMarket Outperform$79.00 from $75.00Sep 9, 2026
Leerink PartnersMaintainedOutperform$65.00 from $50.00Sep 9, 2026
Morgan StanleyMaintainedOverweight$62.00 from $46.00Sep 9, 2026
WedbushMaintainedOutperform$42.00Sep 8, 2026
HC Wainwright & Co.MaintainedBuy$60.00Sep 8, 2026
GuggenheimMaintainedBuy$40.00 from $39.00Aug 13, 2026
RBC CapitalMaintainedOutperform$52.00 from $51.00Aug 13, 2026
CitizensMaintainedMarket Outperform$75.00 from $74.00Aug 13, 2026
Wells FargoInitiated CoverageOverweight$55.00Jul 15, 2026
Morgan StanleyMaintainedOverweight$46.00 from $41.00Jun 25, 2026
CitizensMaintainedMarket Outperform$74.00 from $75.00May 13, 2026
Wolfe ResearchInitiated CoverageOutperform$42.00Apr 9, 2026
WedbushMaintainedOutperform$42.00 from $41.00Apr 7, 2026
RBC CapitalMaintainedOutperform$51.00 from $52.00Apr 6, 2026
RBC CapitalInitiated CoverageOutperform$52.00Mar 9, 2026
HC Wainwright & Co.MaintainedBuy$60.00Mar 3, 2026

Frequently asked questions

  • What is the latest analyst rating on PHVS?

    On Sep 10, 2026, Guggenheim maintained Pharvaris at Buy with a price target of $44.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.